Alectinib as a treatment option following recovery from crizotinib‑induced interstitial lung disease in patients with anaplastic lymphoma kinase‑positive advanced non‑small‑cell lung cancer

  • Authors:
    • Shigenari Nukaga
    • Katsuhiko Naoki
    • Tetsuro Kamo
    • Keita Masuzawa
    • Hiroyuki Yasuda
    • Kenzo Soejima
    • Tomoko Betsuyaku
  • View Affiliations

  • Published online on: March 30, 2016     https://doi.org/10.3892/mco.2016.838
  • Pages: 1085-1087
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Crizotinib is a tyrosine kinase inhibitor that displays antitumor activity against anaplastic lymphoma kinase (ALK)‑positive advanced non‑small‑cell lung cancer. However, crizotinib‑associated interstitial lung disease (ILD) has been reported as an infrequent, but potentially fatal complication. We herein describe the case of a 63‑year‑old male patient with ALK‑rearranged advanced lung adenocarcinoma. Chest computed tomography (CT) revealed extensive bilateral ground‑glass opacity and airspace consolidation with traction bronchiectasis on day 27 of crizotinib therapy. No signs of infection or left heart failure were identified and we considered the lesions to be consistent with crizotinib‑induced ILD. Following corticosteroid treatment and discontinuation of crizotinib, CT revealed improvement of ILD, but also showed regrowth of the tumor. Alectinib, a novel alternative ALK inhibitor, was initiated, and has been successfully continued, with neither disease progression nor recurrence of ILD. The present case indicates that alectinib may be considered as an alternative agent in cases of crizotinib‑induced ILD, irrespective of the pattern of ILD, i.e., a diffuse alveolar damage (DAD) or non‑DAD pattern, with careful observation.
View Figures
View References

Related Articles

Journal Cover

June 2016
Volume 4 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Nukaga, S., Naoki, K., Kamo, T., Masuzawa, K., Yasuda, H., Soejima, K., & Betsuyaku, T. (2016). Alectinib as a treatment option following recovery from crizotinib‑induced interstitial lung disease in patients with anaplastic lymphoma kinase‑positive advanced non‑small‑cell lung cancer. Molecular and Clinical Oncology, 4, 1085-1087. https://doi.org/10.3892/mco.2016.838
MLA
Nukaga, S., Naoki, K., Kamo, T., Masuzawa, K., Yasuda, H., Soejima, K., Betsuyaku, T."Alectinib as a treatment option following recovery from crizotinib‑induced interstitial lung disease in patients with anaplastic lymphoma kinase‑positive advanced non‑small‑cell lung cancer". Molecular and Clinical Oncology 4.6 (2016): 1085-1087.
Chicago
Nukaga, S., Naoki, K., Kamo, T., Masuzawa, K., Yasuda, H., Soejima, K., Betsuyaku, T."Alectinib as a treatment option following recovery from crizotinib‑induced interstitial lung disease in patients with anaplastic lymphoma kinase‑positive advanced non‑small‑cell lung cancer". Molecular and Clinical Oncology 4, no. 6 (2016): 1085-1087. https://doi.org/10.3892/mco.2016.838